Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Mar 21;15(1):9866.
doi: 10.1038/s41598-025-93203-1.

Achieving treatment goals in older breast cancer patients receiving neoadjuvant chemotherapy

Eda Caliskan Yildirim  1 , Elif Atag  2 , Huseyin Salih Semiz  2 , Olcun Umit Unal  3 , Mehmet Uzun  2 , Suleyman Ozkan Aksoy  4 , Merih Guray Durak  5 , Aziz Karaoglu  2
Affiliations

Achieving treatment goals in older breast cancer patients receiving neoadjuvant chemotherapy

Eda Caliskan Yildirim et al. Sci Rep. .

Abstract

Neoadjuvant chemotherapy (NAC) is well-established for locally advanced breast cancer, even in the early stages, especially in HER2-positive and triple-negative cases. However, the effect of chronologic age on NAC response remains controversial. This study investigates the efficacy and outcomes of NAC in older patients with breast cancer, compared to a younger cohort, to address the current knowledge gap. 535 patients who received NAC followed by curative surgery from 2010 to 2021 were retrospectively analyzed. We evaluated breast and axillary downstaging, pathologic complete response (pCR), and post-treatment toxicities. Data were stratified by age, with patients aged 65 years and older representing the older group. Anthracycline-based chemotherapy was prevalent (97.6%) and favored younger patients who received a dose-dense anthracycline regimen (71.7% vs. 38.5%, p < 0.001). Surgical outcomes, breast and axillary downstaging, and the pathologic complete response showed no age-related differences. Grade 3-4 toxicity was higher in older patients (71% vs. 46.4%, p < 0.01). Older patients treated with NAC achieve comparable outcomes to younger patients, supporting personalized treatment. Chronologic age should not dictate treatment decisions, emphasizing the need for comprehensive evaluation for optimal geriatric patient care.

Keywords: Breast cancer; Downstaging; Neoadjuvant chemotherapy; Older patients; PCR.

PubMed Disclaimer

Conflict of interest statement

Declarations. Competing interests: The authors declare no competing interests.

References

    1. Howlader, N. et al. SEER cancer statistics review, 1975–2018. Natl. Cancer Inst. :1–25. (2021).
    1. DeSantis, C. E. et al. Breast cancer statistics, 2019. CA: A Cancer. J. Clin.69, 438–451 (2019). - PubMed
    1. Rapoport, B. L., Demetriou, G. S., Moodley, S. D. & Benn, C. A. When and how do I use neoadjuvant chemotherapy for breast cancer?? Curr. Treat. Options Oncol.15, 86–98 (2014). - PubMed
    1. Hutchins, L. F., Unger, J. M., Crowley, J. J., Coltman, C. A. & Albain, K. S. Underrepresentation of patients 65 years of age or older in Cancer-Treatment trials. N. Engl. J. Med.341, 2061–2067 (1999). - PubMed
    1. von Waldenfels, G. et al. Outcome after neoadjuvant chemotherapy in elderly breast cancer patients – a pooled analysis of individual patient data from eight prospectively randomized controlled trials. Oncotarget ;9. (2018). - PMC - PubMed